Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand.

Treating patients with early-stage breast cancer is less costly than treating those with metastatic disease. The costs vary considerably between the subtypes. Patients with HER2+ cancer incurred three times the costs of those with HER2- cancers. These results provide baseline costing data for clinicians and policy makers when considering new targeted treatments.